During the BLOODPAC Q1 Day 1 recap, the RDE Working Group shared a new project developing Minimum Technical Data Elements (MTDEs) for saliva and buccal samples. An outstanding group of experts is helping shape and accelerate this effort.
#BLOODPAC
#BLOODPAC
March 5, 2026 at 1:39 AM
During the BLOODPAC Q1 Day 1 recap, the RDE Working Group shared a new project developing Minimum Technical Data Elements (MTDEs) for saliva and buccal samples. An outstanding group of experts is helping shape and accelerate this effort.
#BLOODPAC
#BLOODPAC
We're thrilled to announce that BLOODPAC is bringing two dynamic sessions to #AACR25 Annual Meeting—focused on the future of #validation and #performance in blood-based #cancerdetection and #screening.
If you're heading to #AACR25, mark your calendar—we’d love to have you join the conversation.
If you're heading to #AACR25, mark your calendar—we’d love to have you join the conversation.
April 18, 2025 at 6:33 PM
We're thrilled to announce that BLOODPAC is bringing two dynamic sessions to #AACR25 Annual Meeting—focused on the future of #validation and #performance in blood-based #cancerdetection and #screening.
If you're heading to #AACR25, mark your calendar—we’d love to have you join the conversation.
If you're heading to #AACR25, mark your calendar—we’d love to have you join the conversation.
🎥 This video takes us back to our 2022 Summit, celebrating 5 years of BLOODPAC.
Now we’re gearing up for 2027… and the progress since then has been incredible.
Collaboration is accelerating cancer innovation through shared data, standards, and a common mission.
www.youtube.com/watch?v=OQnq...
Now we’re gearing up for 2027… and the progress since then has been incredible.
Collaboration is accelerating cancer innovation through shared data, standards, and a common mission.
www.youtube.com/watch?v=OQnq...
The BLOODPAC Story
YouTube video by BLOODPAC
www.youtube.com
July 28, 2026 at 2:50 PM
🎥 This video takes us back to our 2022 Summit, celebrating 5 years of BLOODPAC.
Now we’re gearing up for 2027… and the progress since then has been incredible.
Collaboration is accelerating cancer innovation through shared data, standards, and a common mission.
www.youtube.com/watch?v=OQnq...
Now we’re gearing up for 2027… and the progress since then has been incredible.
Collaboration is accelerating cancer innovation through shared data, standards, and a common mission.
www.youtube.com/watch?v=OQnq...
🎉 Welcome to BLOODPAC, @Twist Bioscience! 🧬
Twist Bioscience is a biotech company that develops & manufactures synthetic DNA using a silicon-based platform.
To learn more about Twist Bioscience, visit:
👉 www.twistbioscience.com
Twist Bioscience is a biotech company that develops & manufactures synthetic DNA using a silicon-based platform.
To learn more about Twist Bioscience, visit:
👉 www.twistbioscience.com
January 29, 2026 at 3:59 PM
🎉 Welcome to BLOODPAC, @Twist Bioscience! 🧬
Twist Bioscience is a biotech company that develops & manufactures synthetic DNA using a silicon-based platform.
To learn more about Twist Bioscience, visit:
👉 www.twistbioscience.com
Twist Bioscience is a biotech company that develops & manufactures synthetic DNA using a silicon-based platform.
To learn more about Twist Bioscience, visit:
👉 www.twistbioscience.com
We were proud to join #AMP2025!
Our Executive Director, Lauren Leiman, moderated “Demystifying MRD with BLOODPAC,” joined by leaders from Illumina, Harvard, BMS & BLOODPAC to discuss best practices and innovation in cancer monitoring. #MRD #LiquidBiopsy #Oncology
Our Executive Director, Lauren Leiman, moderated “Demystifying MRD with BLOODPAC,” joined by leaders from Illumina, Harvard, BMS & BLOODPAC to discuss best practices and innovation in cancer monitoring. #MRD #LiquidBiopsy #Oncology
November 13, 2025 at 8:21 PM
We were proud to join #AMP2025!
Our Executive Director, Lauren Leiman, moderated “Demystifying MRD with BLOODPAC,” joined by leaders from Illumina, Harvard, BMS & BLOODPAC to discuss best practices and innovation in cancer monitoring. #MRD #LiquidBiopsy #Oncology
Our Executive Director, Lauren Leiman, moderated “Demystifying MRD with BLOODPAC,” joined by leaders from Illumina, Harvard, BMS & BLOODPAC to discuss best practices and innovation in cancer monitoring. #MRD #LiquidBiopsy #Oncology
We're excited to welcome Brian to the BLOODPAC team! 🎉
With 20+ years of experience in data science, bioinformatics, software engineering, and AI/ML, Brian joins us after leadership roles at GT Molecular and Sunbird Bio.
Welcome to BLOODPAC, we're so glad you're here!
With 20+ years of experience in data science, bioinformatics, software engineering, and AI/ML, Brian joins us after leadership roles at GT Molecular and Sunbird Bio.
Welcome to BLOODPAC, we're so glad you're here!
July 9, 2026 at 2:43 PM
We're excited to welcome Brian to the BLOODPAC team! 🎉
With 20+ years of experience in data science, bioinformatics, software engineering, and AI/ML, Brian joins us after leadership roles at GT Molecular and Sunbird Bio.
Welcome to BLOODPAC, we're so glad you're here!
With 20+ years of experience in data science, bioinformatics, software engineering, and AI/ML, Brian joins us after leadership roles at GT Molecular and Sunbird Bio.
Welcome to BLOODPAC, we're so glad you're here!
📘 Ever pause to align on what a term really means?
The BLOODPAC Dictionary makes it easy to find trusted, consensus-built definitions developed by leaders in the field. Bookmark it, share it, reference it—it’s here to support your work.
📖 Use the dictionary here: www.bloodpac.org/bloodpac-dic...
The BLOODPAC Dictionary makes it easy to find trusted, consensus-built definitions developed by leaders in the field. Bookmark it, share it, reference it—it’s here to support your work.
📖 Use the dictionary here: www.bloodpac.org/bloodpac-dic...
August 19, 2025 at 5:37 PM
📘 Ever pause to align on what a term really means?
The BLOODPAC Dictionary makes it easy to find trusted, consensus-built definitions developed by leaders in the field. Bookmark it, share it, reference it—it’s here to support your work.
📖 Use the dictionary here: www.bloodpac.org/bloodpac-dic...
The BLOODPAC Dictionary makes it easy to find trusted, consensus-built definitions developed by leaders in the field. Bookmark it, share it, reference it—it’s here to support your work.
📖 Use the dictionary here: www.bloodpac.org/bloodpac-dic...
Join the @theaacr.bsky.social and @bloodpac.bsky.social at #AACR26 for 𝘾𝙤𝙣𝙩𝙚𝙭𝙩𝙪𝙖𝙡 𝘾𝙝𝙖𝙡𝙡𝙚𝙣𝙜𝙚𝙨 𝙞𝙣 𝙄𝙣𝙩𝙚𝙧𝙥𝙧𝙚𝙩𝙞𝙣𝙜 𝙋𝙚𝙧𝙛𝙤𝙧𝙢𝙖𝙣𝙘𝙚 𝙤𝙛 𝘽𝙡𝙤𝙤𝙙-𝘽𝙖𝙨𝙚𝙙 𝙀𝙖𝙧𝙡𝙮 𝘾𝙖𝙣𝙘𝙚𝙧 𝘿𝙚𝙩𝙚𝙘𝙩𝙞𝙤𝙣 𝙏𝙚𝙨𝙩𝙨: 𝘼 𝘽𝙇𝙊𝙊𝘿𝙋𝘼𝘾 𝙋𝙚𝙧𝙨𝙥𝙚𝙘𝙩𝙞𝙫𝙚
🔗 www.abstractsonline.com/pp8/#!/21436...
🔗 www.abstractsonline.com/pp8/#!/21436...
April 15, 2026 at 4:44 PM
Join the @theaacr.bsky.social and @bloodpac.bsky.social at #AACR26 for 𝘾𝙤𝙣𝙩𝙚𝙭𝙩𝙪𝙖𝙡 𝘾𝙝𝙖𝙡𝙡𝙚𝙣𝙜𝙚𝙨 𝙞𝙣 𝙄𝙣𝙩𝙚𝙧𝙥𝙧𝙚𝙩𝙞𝙣𝙜 𝙋𝙚𝙧𝙛𝙤𝙧𝙢𝙖𝙣𝙘𝙚 𝙤𝙛 𝘽𝙡𝙤𝙤𝙙-𝘽𝙖𝙨𝙚𝙙 𝙀𝙖𝙧𝙡𝙮 𝘾𝙖𝙣𝙘𝙚𝙧 𝘿𝙚𝙩𝙚𝙘𝙩𝙞𝙤𝙣 𝙏𝙚𝙨𝙩𝙨: 𝘼 𝘽𝙇𝙊𝙊𝘿𝙋𝘼𝘾 𝙋𝙚𝙧𝙨𝙥𝙚𝙘𝙩𝙞𝙫𝙚
🔗 www.abstractsonline.com/pp8/#!/21436...
🔗 www.abstractsonline.com/pp8/#!/21436...
We are pleased to welcome @eortc.org as BLOODPAC’s newest member. EORTC is an international, nonprofit cancer research organization coordinating clinical and translational studies to help improve patient outcomes worldwide.
#BLOODPAC #CancerResearch
#BLOODPAC #CancerResearch
March 11, 2026 at 1:25 PM
We are pleased to welcome @eortc.org as BLOODPAC’s newest member. EORTC is an international, nonprofit cancer research organization coordinating clinical and translational studies to help improve patient outcomes worldwide.
#BLOODPAC #CancerResearch
#BLOODPAC #CancerResearch
We’re pleased to welcome @zymoresearch.bsky.social as the newest member of BLOODPAC!
Zymo Research develops molecular biology products and services supporting sample collection and preservation, DNA/RNA purification, epigenetics, microbiomics, and NGS research applications.
Zymo Research develops molecular biology products and services supporting sample collection and preservation, DNA/RNA purification, epigenetics, microbiomics, and NGS research applications.
May 26, 2026 at 3:51 PM
We’re pleased to welcome @zymoresearch.bsky.social as the newest member of BLOODPAC!
Zymo Research develops molecular biology products and services supporting sample collection and preservation, DNA/RNA purification, epigenetics, microbiomics, and NGS research applications.
Zymo Research develops molecular biology products and services supporting sample collection and preservation, DNA/RNA purification, epigenetics, microbiomics, and NGS research applications.
Looking ahead to IQN Path Annual Meeting in May - our Executive Director will present on advancing collaboration to accelerate implementation, highlighting BLOODPAC initiatives and Global Regulatory Working Group efforts. Join us in Naples!
April 30, 2026 at 5:11 PM
Looking ahead to IQN Path Annual Meeting in May - our Executive Director will present on advancing collaboration to accelerate implementation, highlighting BLOODPAC initiatives and Global Regulatory Working Group efforts. Join us in Naples!
Zymo Research has joined the Blood Profiling Atlas in Cancer (#BLOODPAC) Consortium, a nonprofit coalition accelerating the development, validation, and accessibility of liquid biopsy assays for precision medicine.
Read the full press release: https://ow.ly/k6M350ZiuLT
Read the full press release: https://ow.ly/k6M350ZiuLT
June 30, 2026 at 2:30 PM
Zymo Research has joined the Blood Profiling Atlas in Cancer (#BLOODPAC) Consortium, a nonprofit coalition accelerating the development, validation, and accessibility of liquid biopsy assays for precision medicine.
Read the full press release: https://ow.ly/k6M350ZiuLT
Read the full press release: https://ow.ly/k6M350ZiuLT
#ICYMI our 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘢𝘯𝘥 𝘛𝘳𝘢𝘯𝘴𝘭𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘚𝘤𝘪𝘦𝘯𝘤𝘦 paper “𝐄𝐬𝐭𝐚𝐛𝐥𝐢𝐬𝐡𝐢𝐧𝐠 𝐚 𝐂𝐨𝐦𝐦𝐨𝐧 𝐋𝐞𝐱𝐢𝐜𝐨𝐧 𝐟𝐨𝐫 𝐂𝐢𝐫𝐜𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐓𝐮𝐦𝐨𝐫 𝐃𝐍𝐀 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐧𝐝 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐑𝐞𝐬𝐢𝐝𝐮𝐚𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐅𝐫𝐨𝐦 𝐭𝐡𝐞 𝐁𝐋𝐎𝐎𝐃𝐏𝐀𝐂 𝐂𝐨𝐧𝐬𝐨𝐫𝐭𝐢𝐮𝐦” is paper of the month! Thank you @ascptclinpharm.bsky.social!
📖 ascpt.onlinelibrary.wiley.com/doi/10.1111/...
📖 ascpt.onlinelibrary.wiley.com/doi/10.1111/...
July 24, 2025 at 6:39 PM
#ICYMI our 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘢𝘯𝘥 𝘛𝘳𝘢𝘯𝘴𝘭𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘚𝘤𝘪𝘦𝘯𝘤𝘦 paper “𝐄𝐬𝐭𝐚𝐛𝐥𝐢𝐬𝐡𝐢𝐧𝐠 𝐚 𝐂𝐨𝐦𝐦𝐨𝐧 𝐋𝐞𝐱𝐢𝐜𝐨𝐧 𝐟𝐨𝐫 𝐂𝐢𝐫𝐜𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐓𝐮𝐦𝐨𝐫 𝐃𝐍𝐀 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐧𝐝 𝐌𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐑𝐞𝐬𝐢𝐝𝐮𝐚𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞: 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐅𝐫𝐨𝐦 𝐭𝐡𝐞 𝐁𝐋𝐎𝐎𝐃𝐏𝐀𝐂 𝐂𝐨𝐧𝐬𝐨𝐫𝐭𝐢𝐮𝐦” is paper of the month! Thank you @ascptclinpharm.bsky.social!
📖 ascpt.onlinelibrary.wiley.com/doi/10.1111/...
📖 ascpt.onlinelibrary.wiley.com/doi/10.1111/...
BLOODPAC expands its data standards for #liquidbiopsy research with 22 clinical and 10 patient context data elements. Standardizing what we collect helps move these tools closer to routine care.
👉Read more here: ascpt.onlinelibrary.wiley.com/doi/10.1111/...
👉Read more here: ascpt.onlinelibrary.wiley.com/doi/10.1111/...
July 16, 2025 at 5:18 PM
BLOODPAC expands its data standards for #liquidbiopsy research with 22 clinical and 10 patient context data elements. Standardizing what we collect helps move these tools closer to routine care.
👉Read more here: ascpt.onlinelibrary.wiley.com/doi/10.1111/...
👉Read more here: ascpt.onlinelibrary.wiley.com/doi/10.1111/...
We're pleased to welcome @bloodcancerunited.bsky.social to BLOODPAC! Blood Cancer United is a global nonprofit focused on blood cancer patient support, research, and advocacy. We look forward to collaborating to advance liquid biopsy innovation for patients. Learn more: bloodcancerunited.org
August 4, 2026 at 4:34 PM
We're pleased to welcome @bloodcancerunited.bsky.social to BLOODPAC! Blood Cancer United is a global nonprofit focused on blood cancer patient support, research, and advocacy. We look forward to collaborating to advance liquid biopsy innovation for patients. Learn more: bloodcancerunited.org
Big shoutout to Jenn Lococo for repping BLOODPAC at the #PROMETHEUS retreat in DC!
She + Adam Corner are leading the group effort on #ctDNA testing quality + consistency across labs.
And yes, we see you Jerry + Danne 😎📸
👉JFDI initial paper: www.sciencedirect.com/science/arti...
#liquidbiopsy
She + Adam Corner are leading the group effort on #ctDNA testing quality + consistency across labs.
And yes, we see you Jerry + Danne 😎📸
👉JFDI initial paper: www.sciencedirect.com/science/arti...
#liquidbiopsy
July 25, 2025 at 5:43 PM
Big shoutout to Jenn Lococo for repping BLOODPAC at the #PROMETHEUS retreat in DC!
She + Adam Corner are leading the group effort on #ctDNA testing quality + consistency across labs.
And yes, we see you Jerry + Danne 😎📸
👉JFDI initial paper: www.sciencedirect.com/science/arti...
#liquidbiopsy
She + Adam Corner are leading the group effort on #ctDNA testing quality + consistency across labs.
And yes, we see you Jerry + Danne 😎📸
👉JFDI initial paper: www.sciencedirect.com/science/arti...
#liquidbiopsy
🔊BLOODPAC member Ghent University has been published in Nature Communications.
💡Their study provides valuable insights for the liquid biopsy community. The underlying data is available to our members in our Data Commons.
📖 Read the full article:https://www.nature.com/articles/s41467-025-58607-7
💡Their study provides valuable insights for the liquid biopsy community. The underlying data is available to our members in our Data Commons.
📖 Read the full article:https://www.nature.com/articles/s41467-025-58607-7
May 27, 2025 at 2:35 PM
🔊BLOODPAC member Ghent University has been published in Nature Communications.
💡Their study provides valuable insights for the liquid biopsy community. The underlying data is available to our members in our Data Commons.
📖 Read the full article:https://www.nature.com/articles/s41467-025-58607-7
💡Their study provides valuable insights for the liquid biopsy community. The underlying data is available to our members in our Data Commons.
📖 Read the full article:https://www.nature.com/articles/s41467-025-58607-7
We are thrilled to welcome SAGA Diagnostics to the BLOODPAC community! The have developed a novel tumor-informed MRD platform based on structural variant biology that helps to detect residual disease post-curative intent therapy and monitor response to therapy.
Learn more here: sagadiagnostics.com
Learn more here: sagadiagnostics.com
May 12, 2025 at 2:45 PM
We are thrilled to welcome SAGA Diagnostics to the BLOODPAC community! The have developed a novel tumor-informed MRD platform based on structural variant biology that helps to detect residual disease post-curative intent therapy and monitor response to therapy.
Learn more here: sagadiagnostics.com
Learn more here: sagadiagnostics.com
Just one week until BLOODPAC’s Q3 2026 in-person meeting!
We look forward to welcoming members and collaborators to Chicago on September 9–10 for two days of discussion, collaboration, and progress across BLOODPAC initiatives.
We look forward to welcoming members and collaborators to Chicago on September 9–10 for two days of discussion, collaboration, and progress across BLOODPAC initiatives.
September 2, 2026 at 3:28 PM
Just one week until BLOODPAC’s Q3 2026 in-person meeting!
We look forward to welcoming members and collaborators to Chicago on September 9–10 for two days of discussion, collaboration, and progress across BLOODPAC initiatives.
We look forward to welcoming members and collaborators to Chicago on September 9–10 for two days of discussion, collaboration, and progress across BLOODPAC initiatives.
The Josep Carreras Institute has joined #BLOODPAC, an international consortium working to advance liquid biopsy research and its clinical implementation.
🔗 Find out more: www.carrerasresearch.org/en/news/the-...
🔗 Find out more: www.carrerasresearch.org/en/news/the-...
September 2, 2026 at 6:15 AM
The Josep Carreras Institute has joined #BLOODPAC, an international consortium working to advance liquid biopsy research and its clinical implementation.
🔗 Find out more: www.carrerasresearch.org/en/news/the-...
🔗 Find out more: www.carrerasresearch.org/en/news/the-...
“I’ve been with BLOODPAC for about eight years, and we’re just starting a clinical utility working group focused on MRD. If you’re interested in helping us advance MRD testing for patients, please join us.” A Q1 takeaway from Girish Putcha.
Looking ahead to Q3 in September. #LiquidBiopsy #MRD
Looking ahead to Q3 in September. #LiquidBiopsy #MRD
August 27, 2026 at 3:19 PM
“I’ve been with BLOODPAC for about eight years, and we’re just starting a clinical utility working group focused on MRD. If you’re interested in helping us advance MRD testing for patients, please join us.” A Q1 takeaway from Girish Putcha.
Looking ahead to Q3 in September. #LiquidBiopsy #MRD
Looking ahead to Q3 in September. #LiquidBiopsy #MRD
We’re excited to join the @BLOODPAC community and collaborate with others working to advance liquid biopsy technologies. We look forward to sharing knowledge, learning from fellow members, and contributing to the development of practical pre-analytical best practices.
Learn more: bit.ly/45zxA7n
Learn more: bit.ly/45zxA7n
Please join us in welcoming @stemcell.com as BLOODPAC’s newest member! STEMCELL develops cell culture media, cell separation technologies, instruments, & resources supporting research in stem cell biology, immunology, cancer, regenerative medicine, and cellular therapy. Learn more: www.stemcell.com
August 26, 2026 at 8:09 PM
We’re excited to join the @BLOODPAC community and collaborate with others working to advance liquid biopsy technologies. We look forward to sharing knowledge, learning from fellow members, and contributing to the development of practical pre-analytical best practices.
Learn more: bit.ly/45zxA7n
Learn more: bit.ly/45zxA7n
"We’re seeing collaboration across industry, diagnostics, pharma, academia, and regulatory partners that isn’t possible anywhere else—bringing the liquid biopsy ecosystem together with a shared goal of patient impact.” —Darya, Q1 BLOODPAC Meeting.
#LiquidBiopsy
Looking ahead to Q3 in September.
#LiquidBiopsy
Looking ahead to Q3 in September.
August 20, 2026 at 2:54 PM
"We’re seeing collaboration across industry, diagnostics, pharma, academia, and regulatory partners that isn’t possible anywhere else—bringing the liquid biopsy ecosystem together with a shared goal of patient impact.” —Darya, Q1 BLOODPAC Meeting.
#LiquidBiopsy
Looking ahead to Q3 in September.
#LiquidBiopsy
Looking ahead to Q3 in September.
"We’re seeing collaboration across industry, diagnostics, pharma, academia, and regulatory partners that isn’t possible anywhere else—bringing the liquid biopsy ecosystem together with a shared goal of patient impact.” —Darya, Q1 BLOODPAC Meeting.
#LiquidBiopsy
Looking ahead to Q3 in September.
#LiquidBiopsy
Looking ahead to Q3 in September.
August 20, 2026 at 2:54 PM
"We’re seeing collaboration across industry, diagnostics, pharma, academia, and regulatory partners that isn’t possible anywhere else—bringing the liquid biopsy ecosystem together with a shared goal of patient impact.” —Darya, Q1 BLOODPAC Meeting.
#LiquidBiopsy
Looking ahead to Q3 in September.
#LiquidBiopsy
Looking ahead to Q3 in September.
"This is my first visit to BLOODPAC, and I think it’s an amazing organization. Everyone here is benefiting from what’s happening in the scientific world—understanding regulations and working toward solutions that will help people, especially in diagnostics.” —Alex Chauhan
Looking forward to our Q3!
Looking forward to our Q3!
August 13, 2026 at 3:24 PM
"This is my first visit to BLOODPAC, and I think it’s an amazing organization. Everyone here is benefiting from what’s happening in the scientific world—understanding regulations and working toward solutions that will help people, especially in diagnostics.” —Alex Chauhan
Looking forward to our Q3!
Looking forward to our Q3!